ClinicalTrials.gg
Not yet recruitingNCT07191028ATHENE IIUpdated Jun 12, 2026

Alzheimer's Disease THErapy With NEuroaid II

A Phase 3 interventional study of MLC 901 and Placebo in Alzheimer's Disease Dementia, sponsored by Moleac Pte Ltd.. Not yet recruiting at 1 site in Singapore. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by Moleac Pte Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
350
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Alzheimer Disease with a site in Singapore — 6 open to participants now, 10 under way, 4 of them phase 3. Alzheimer Disease · Singapore.

Planned enrollment
15th of 25
350 · median 587
Started
2026
with 2 others
Phase 3
13 of 27
2 open now
Registered
25th of 27
by date

Among the 27 studies in Alzheimer Disease with a site in Singapore, this one is the 15th largest by planned enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2026, is one of 13 in phase 3, and was the 25th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

6 of the 27 studies in Alzheimer Disease with a site in Singapore are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Alzheimer Disease with a site in Singapore, or all of them as a file.
02

Study summary

ATHENE II is a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial designed to evaluate the efficacy and safety of MLC901 in subjects with mild to moderate Alzheimer's disease, as well as its effects on plasma biomarkers compared to placebo.

Read the detailed description

Alzheimer's disease (AD) is a progressive neurodegenerative disorder with limited treatments that slow progression. Current symptomatic therapies provide modest benefit, while anti-amyloid agents target a single pathway and have uncertain long-term outcomes. Multitarget approaches may provide broader and more durable benefit. MLC901 (NeuroAiD™II), a Traditional Chinese Medicine derived formulation, has shown neuroprotective and neuroproliferative properties in preclinical studies through multimodal mechanisms, including modulation of amyloid beta and tau phosphorylation, reduction of oxidative stress and inflammation, and promotion of neurogenesis and synaptogenesis. Clinical studies, including the ATHENE trial, suggest MLC901 may slow cognitive decline and is well tolerated. ATHENE II is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study enrolling approximately 350 patients with mild to moderate AD across Southeast Asia. Participants will receive MLC901 or placebo for 12 months. The primary objective is to determine whether MLC901 is superior to placebo in slowing cognitive decline as measured by ADAS-Cog11. Secondary and exploratory objectives include global cognition, function, behavior, safety, and plasma biomarkers of AD (p-tau217, NfL and GFAP).

03

Conditions studied

  • Alzheimer's Disease Dementia

Browse trials for

Keywords

  • MLC901
  • NeuroAiD™II
  • Alzheimer's disease
  • multicenter
  • randomised
  • double blind
  • placebo controlled
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects aged ≥ 50 years at the time of providing .
  • Diagnosis of AD based on the National Institute on Ageing and the Alzheimer's Association (NIA-AA) criteria, supported by the presence of a Core 1 AD biomarker, specifically elevated plasma ptau217 ≥0.471 pg/mL.
  • score between 10 and 26, inclusive, at baseline, corresponding to mild to moderate AD.
  • Subjects may be either treatment-naïve or currently receiving stable symptomatic treatment for AD for at least the 2 months prior to screening, including AChEIs, memantine, or a combination of both.
  • Subjects must have a designated study partner who provides ongoing support during the study and interacts with the subject for a minimum of 8 hours per week, and will accompany the subject to study visits or be available by telephone at designated times.

A second study partner may serve as backup. If the original study partner withdraws from participation, a replacement study partner may be permitted at the investigator's discretion. The replacement study partner must provide informed consent prior to their first study visit with the subject.

  • Both the subject (or their legally authorized representative) and the study partner(s) must be capable of providing informed consent.
  • Subjects must have adequate literacy, vision, and hearing, in the opinion of the investigator at the time of screening, to allow for valid administration of the clinical outcome assessments.

Exclusion criteria

Exclusion Criteria:

  • Presence of any neurological disorder contributing to cognitive impairment other than AD, including but not limited to: Parkinson's disease, Dementia with Lewy bodies, and epilepsy or recurrent seizures.
  • Evidence of other cerebrovascular disease or intracranial abnormalities based on the latest brain CT or MRI, including but not limited to: multiple lacunar infarcts, large territorial infarcts, severe small vessel or white matter disease, normal pressure hydrocephalus, space occupying lesions.

The most recent available scan (obtained at diagnosis or subsequently) is usually sufficient for screening eligibility to exclude these other conditions. Repeat imaging may need in some cases to be considered if there is clinically significant deterioration or new neurological signs suggestive of a cerebrovascular event.

  • Presence of any serious or unstable medical illnesses, including but not limited to: cardiovascular, respiratory, gastroenterological, endocrinologic, immunologic, hematologic, hepatic, or renal and other conditions, that, in the investigator's judgment, may interfere with study participation or compromise subject safety.
  • Patients with a CDR Global Score of 0, 0.5 or 3 at the Screening Phase, corresponding to no, very mild or severe dementia, respectively, will be excluded from the study.
  • Severe visual or hearing impairment that would prevent the subject from accurately completing clinical outcome assessments.
  • Serum creatinine > 130 µmol/L at baseline, which may affect plasma biomarker analysis.
  • Female subjects who are pregnant at screening.
  • Participation in another clinical trial or receipt of any product within 60 days or 5 half-lives (whichever is longer) prior to screening.
  • Current use at baseline of any AD disease modifying therapies including anti-amyloid therapy or neuroprotective/nootropic agents, including Ginkgo biloba, Neurotain, Citicoline, Cerebrolysin, or Piracetam.
  • Known or allergic reaction to MLC901 or any of its components. Any known food allergy or hypersensitivity to Astragalus membranaceus, Ligusticum chuanxiong, Polygala tenuifolia, Angelica sinensis or members of the Fabaceae/Leguminosae family (e.g., legume, pea, bean), Polygalaceae family (e.g., milkwort, snakeroot), Apiaceae/Umbelliferae family (e.g., anise, caraway, carrot, celery, dill, parsley, parsnip) or Quillaja bark (soapbark).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
350 participants (estimated)

Study arms

  • Experimental
    MLC901

    Active arm

    Drug: MLC 901

  • Placebo comparator
    Placebo

    Matching placebo

    Drug: Placebo

Interventions

  • Oral capsule, 2 capsules 3 times a day for 12 months

  • DrugPlacebo

    Oral capsule, 2 capsules 3 times a day for 12 months

06

What researchers measure

Primary outcomes

  1. Alzheimer's Disease Assessment Scale-Cognitive Subscale11 (ADAS-Cog11)

    The ADAS-Cog is a rater-administered instrument designed to assess the severity of cognitive impairment and associated non-cognitive behaviors characteristic of individuals with AD. It is the most widely used cognitive scale in clinical trials evaluating treatments for mild to moderate AD. For this study, the version of ADAS-Cog11 will be used as the primary efficacy assessment. The ADAS Cog11 consists of 11 items assessing key areas of cognitive function that are commonly impaired in AD, including: orientation, word recall, word recognition, remembering word recognition test instructions, commands, comprehension of spoken language, naming, word-finding difficulty, spoken language ability, construction praxis, and ideational praxis. The ADAS-Cog11 total score ranges from 0 to 70, with higher scores indicating greater cognitive impairment.

    Time frame: Baseline, Month 6 and Month 12

Secondary outcomes

  1. Clinical Dementia Rating (CDR): Global Score and Sum of Boxes (CDR-SB)

    The CDR evaluates both cognitive and functional domains through structured interviews conducted with both the participant and a knowledgeable informant (such as a caregiver or study partner). The assessment is administered by a trained assessor according to a standardized protocol. The CDR includes the following 6 domains: 3 cognitive domains (memory, orientation, and judgment/problem solving) and 3 functional domains (community activities, home and leisure, and personal care). Each domain is rated on a scale from 0 (no impairment) to 3 (severe impairment). The CDR yield 2 scores, including CDR Global Score and CDR-SB. The CDR global score: a categorical rating from 0 to 3, derived via a standardized algorithm. This score is used to stage the severity of dementia as follows: 0= No dementia; 0.5= Very mild dementia; 1= Mild dementia; 2= Moderate dementia; 3= Severe dementia. CDR-SB: a continuous score ranging from 0 to 18, calculated by summing the individual domain scores.

    Time frame: Baseline, Month 6 and Month 12

  2. Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)

    The ADCS-ADL, developed by Galasko et al, is the most widely used instrument for assessing functional outcomes in patients with AD. This 23-item scale evaluates both basic activities of daily living-such as eating and toileting-and more complex instrumental activities of daily living. The ADCS-ADL is administered as a structured interview with the participant's study partner or caregiver. For each item, the study partner is first asked whether the participant attempted the activity within the past four weeks. If so, the study partner is then asked to describe the participant's performance, which is scored accordingly. The total ADCS-ADL score ranges from 0 to 78, with lower scores indicating greater functional impairment.

    Time frame: Baseline, Month 6 and Month 12

  3. Neuropsychiatric Inventory (NPI)

    The NPI is a validated instrument developed to assess a broad spectrum of behavioral and psychological symptoms commonly observed in individuals with dementia. The purpose of the NPI is to characterize the presence and severity of these symptoms. The questionnaire assesses 12 neuropsychiatric symptom domains: delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, aberrant motor behavior, nighttime disturbances, and appetite/eating abnormalities. For each symptom domain, both frequency and severity are assessed. Severity is rated on a 3-point scale (mild, moderate, or marked), while caregiver distress related to each symptom is also rated on a 6-point scale (ranging from no distress to very severe distress). The NPI is administered via a structured interview with the subject's study partner or caregiver, who provides observations based on the subject's behavior.

    Time frame: Baseline, Month 6 and Month 12

  4. Adverse events

    Listing and calculating the number and percentage of subjects experiencing non-serious and serious adverse events for each arm.

    Time frame: Up to 52 weeks

Other outcomes

  1. Plasma biomarkers - phosphorylated tau (p-tau217)

    Plasma samples will be collected from all subjects and used for research purposes to identify dynamic biomarkers that may be predictive of treatment response to MLC901. During screening, at baseline and subsequent visits as detailed in the Schedule of Events, whole blood samples will be obtained from every subject who has consented to participate in the study. The plasma samples will be used to evaluate p-tau217 in pg/mL.

    Time frame: Baseline and Month 12

  2. Plasma biomarkers - neurofilament light chain (NfL)

    Plasma samples will be collected from all subjects and used for research purposes to identify dynamic biomarkers that may be predictive of treatment response to MLC901. During screening, at baseline and subsequent visits as detailed in the Schedule of Events, whole blood samples will be obtained from every subject who has consented to participate in the study. The plasma samples will be used to evaluate NfL in pg/mL.

    Time frame: Baseline and Month 12

  3. Plasma biomarkers - glial fibrillary acidic protein (GFAP)

    Plasma samples will be collected from all subjects and used for research purposes to identify dynamic biomarkers that may be predictive of treatment response to MLC901. During screening, at baseline and subsequent visits as detailed in the Schedule of Events, whole blood samples will be obtained from every subject who has consented to participate in the study. The plasma samples will be used to evaluate GFAP in pg/mL.

    Time frame: Baseline and Month 12

07

Study locations

1 site
08

References and documents

Publications

  • Dib M, Ampil E, Kee HF, et al. A review of NeuroAiD™ II (MLC901) development in Alzheimer's disease treatment: promises of a multimodal pathway. J Neurol Res Rev Rep. 2022 Jun 30;1-13.
  • Lee WT, Hsian CCL, Lim YA. The effects of MLC901 on tau phosphorylation. Neuroreport. 2017 Nov 8;28(16):1043-1048. doi: 10.1097/WNR.0000000000000884. PubMed 28902708 ↗
  • Lim YA, Murray LA, Lai MK, Chen C. NeuroAiD(R) (MLC601) and amyloid precursor protein processing. Cerebrovasc Dis. 2013;35 Suppl 1:30-7. doi: 10.1159/000346236. Epub 2013 Mar 14. PubMed 23548917 ↗
  • Heurteaux C, Widmann C, Moha ou Maati H, Quintard H, Gandin C, Borsotto M, Veyssiere J, Onteniente B, Lazdunski M. NeuroAiD: properties for neuroprotection and neurorepair. Cerebrovasc Dis. 2013;35 Suppl 1:1-7. doi: 10.1159/000346228. Epub 2013 Mar 14. PubMed 23548913 ↗
  • Heurteaux C, Gandin C, Borsotto M, Widmann C, Brau F, Lhuillier M, Onteniente B, Lazdunski M. Neuroprotective and neuroproliferative activities of NeuroAid (MLC601, MLC901), a Chinese medicine, in vitro and in vivo. Neuropharmacology. 2010 Jun;58(7):987-1001. doi: 10.1016/j.neuropharm.2010.01.001. Epub 2010 Jan 11. PubMed 20064536 ↗

Individual participant data

Plan to share: No — There are no plans to share individual participant data (IPD) for this study. Only de-identified, aggregate study findings will be disseminated through scientific meetings and peer-reviewed publications.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Feb 2029, 30 months later.

Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's planned 30 months is below that.

Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2025
First posted
Sep 24, 2025
StartEst.
Aug 2026
Primary completionEst.
Feb 2029
CompletionEst.
May 2029
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07191028
Lead sponsor
Moleac Pte Ltd.
Responsible party
Sponsor
First posted
Sep 24, 2025
Start date
Aug 2026 (estimated)
Primary completion
Feb 2029 (estimated)
Completion
May 2029 (estimated)
Last update
Jun 12, 2026

Study contacts

Mei Fen Sung
Contact
mea.sung@moleac.com
+65 62113710 ext. 183
Peak Yuen Lee
Contact
peakyuen.lee@moleac.com
+65 62113710 ext. 185
Christopher Li Hsian Chen
principal investigator · National University Hospital, Singapore

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Neuroaid

Start the discussion